Breast cancer patients expressing high levels of PRMT1 but low levels of USP11 are associated with a poor survival rate (Supplementary Fig. 7), which could be a consequence of defective end-resection thereby favouring error-prone NHEJ and genome instability. Here, PRMT1 is linked to breast carcinoma.